louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04941118: Myofascial Pain Syndrome and Dextrose Prolotherapy
Official title: Evaluation of the Effect of Dextrose Prolotherapy on Pain and Function in Women With Myofascial Pain Syndrome
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Efficacy of Dextrose Prolotherapy in Myofascial Pain Syndrome
Keywords: Myofascial pain, dextrose prolotherapy, neck disability
Lead sponsor: Mustafa Kemal University
Sponsor class: OTHER
First posted: 2021-06-28
Enrollment: 60
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Myofascial pain syndrome is characterized by the presence of hypersensitive points called trigger points that cause pain, tenderness, spasm, stiffness, limitation of movement, weakness, taut band within the muscle, and pain reflected by pressing in a muscle group or a single muscle.

Prolotherapy is a regenerative treatment method in the treatment of chronic musculoskeletal pain, in which an irritating solution is injected, often hypertonic dextrose, into painful ligament and tendon attachments and adjacent joint spaces.

In this study, it was aimed to examine the effect of prolotherapy application on pain, neck range of motion and neck disability in women with myofascial pain syndrome.


Eligibility criteria: Inclusion Criteria:

* 60 women aged 20-50 years with a diagnosis of myofascial pain syndrome

Exclusion Criteria:

* Cervical radiculopathy, cervical degeneration, neck surgery or trauma in the last year, injection history for myofascial pain syndrome in the last 6 months, cognitive impairment and fibromyalgia, rheumatoid arthritis, hypothyroidism, diabetes mellitus

Primary outcomes:
measure: Visual Analog Scale
timeFrame: First month post-treatment
measure: Neck Disability Index
timeFrame: First month post-treatment
measure: Neck joint range of motion measurement
timeFrame: First month post-treatment
Secondary outcomes:
measure: Side effects
timeFrame: Through study completion, an average of 6 month.
Other outcomes:
Locations:
city: Hatay
country: Turkey
facility: Hatay Mustafa Kemal University, Tayfur Ata Sökmen Faculty of Medicine
Study officials:
References:
citation: Farpour HR, Fereydooni F. Comparative effectiveness of intra-articular prolotherapy versus peri-articular prolotherapy on pain reduction and improving function in patients with knee osteoarthritis: A randomized clinical trial. Electron Physician. 2017 Nov 25;9(11):5663-5669. doi: 10.19082/5663. eCollection 2017 Nov.
citation: Rabago D, Patterson JJ, Mundt M, Kijowski R, Grettie J, Segal NA, Zgierska A. Dextrose prolotherapy for knee osteoarthritis: a randomized controlled trial. Ann Fam Med. 2013 May-Jun;11(3):229-37. doi: 10.1370/afm.1504.
Clinical trial NCT05090618: The Role of Genetic Factors in the Development of Myocardial Infarction in the Kazakh Population
Official title: Preventive and Personalized Medicine (2021-2023)
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Heart Attack
Keywords: GWAS
Lead sponsor: Asfendiyarov Kazakh National Medical University
Sponsor class: OTHER
First posted: 2021-10-25
Enrollment: 500
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: KAZAKH POPULATION

Brief summary: This is a GWAS study that aims to identify possible candidate genes associate to heart attack by exploring single nucleotide polymorphism (SNP) in a group of heart attack, in the Kazakh population. The investigators hypothesize that the careful phenotyping of the subject sand matching with increase the power to find SNP significantly associate with heart attack

Detailed description: A genome-wide association study (GWAS) is an approach used in genetics research to associate specific genetic variations with particular diseases. The method involves scanning the genomes from many different people and looking for genetic markers that can be used to predict the presence of a disease. Once such genetic markers are identified, they can be used to understand how genes contribute to the disease and develop better prevention and treatment strategies.

Eligibility criteria: Inclusion Criteria:

* Persons of Kazakh nationality
* Age up to 59 years inclusive at the time of primary myocardial infarction
* Myocardial infarction was established in accordance with the EOC criteria: An increase and / or decrease in the level of cardiac troponin must be combined with at least one of the following: • Symptoms of myocardial ischemia • Newly occurring ischemic changes on the ECG • The appearance of a pathological Q wave • Identification according to imaging data methods of new areas of non-viable myocardium, or new areas of local contractility disorders of presumably ischemic etiology • Detection of a thrombus in the coronary arteries according to coronary angiography
* Presence of coronary angiography
* Persons able and willing to provide written informed consent;

Exclusion Criteria:

* Age at primary myocardial infarction 60 years and older
* Heart defects, congenital and acquired
* Non-ischemic cardiomyopathies
* Autoimmune diseases
* Diabetes mellitus at the time of development of primary myocardial infarction
* Terminal stages of renal and hepatic failure

Primary outcomes:
measure: number of SNPs associated with Heart Attack
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Almaty
country: Kazakhstan
facility: Kazakhstan
Study officials:
affiliation: Research Institute of Cardiology and Internal Medicine
name: Aisulu Mussagaliyeva, PhD
role: STUDY_DIRECTOR
affiliation: Research Institute of Cardiology and Internal Medicine
name: Roza Kuanyshbekova
role: STUDY_DIRECTOR
References:
Clinical trial NCT05362318: Project HEALS (Helping and Empowering pAtients for Living a Life Smoke-free
Official title: Motivating Smoking Cessation and Relapse Prevention Among Lung Cancer Patients: Helping and Empowering pAtients for Living a Life Smoke-free (Project HEALS)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Smoking
Tobacco Use
Lung Cancer
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute
Sponsor class: OTHER
First posted: 2022-05-05
Enrollment: 21
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The purpose of the study is to pilot test a multi-modal smoking cessation and relapse prevention intervention with the lung cancer patient population and to obtain preliminary data on its feasibility.


Eligibility criteria: Inclusion Criteria:

* 18 years of age or older
* Smoked at least 100 cigarettes in lifetime
* Current smoking (defined as self-report of any smoking, even a puff, in the past 30 days)
* Diagnosis of lung cancer
* Able to read and write English
* Not currently enrolled in a smoking cessation program
* Has a working telephone
* Has a valid home address

Exclusion Criteria:

* Current use of tobacco cessation medications
* Another household member enrolled in this study
* Contraindication of nicotine patch, unless under the supervision of a physician as advised by project staff
* Moffitt clinical trial participant at time of enrollment

Primary outcomes:
measure: Percentage of Participants who meet inclusion criteria
timeFrame: Baseline
measure: Percentage of participants who agree to participate in the study
timeFrame: Baseline
measure: Percentage of participants completing baseline assessment
timeFrame: Baseline
measure: Percentage of participants completing the 3 month follow-up assessments
timeFrame: at 3 months
measure: Percentage of participants completing the 6 month follow-up assessments
timeFrame: at 6 months
measure: Treatment satisfaction - Acceptability
timeFrame: at 6 months
measure: Completion rate of MAPS calls for UC+MAPS+RP participants - Demand
timeFrame: at 6 months
measure: Percentage of UC+MAPS+RP participants who viewed the web-based video -Demand
timeFrame: at 3 months
measure: Percentage of UC+MAPS+RP participants who viewed the web-based video -Demand
timeFrame: at 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Tampa
country: United States
facility: Moffitt Cancer Center
state: Florida
Study officials:
affiliation: Moffitt Cancer Center
name: Vani N Simmons, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: Moffitt Cancer Center
name: Jennifer I Vidrine, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04031118: Corneal Oxygen Uptake With Apioc Contact Lenses
Official title: Corneal Oxygen Uptake With Apioc Contact Lenses
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Contact Lens-Induced Corneal Disorder of Both Eyes (Diagnosis)
Lead sponsor: Lentechs, LLC
Sponsor class: INDUSTRY
First posted: 2019-07-24
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DEVICE_FEASIBILITY

Brief summary: The purpose of this research is to determine if a new investigational contact lens shape allows the eye to get more oxygen.


Eligibility criteria: Inclusion Criteria:

1. Provide informed consent.
2. Appear willing and able to adhere to instructions set forth in the protocol.
3. Be between the ages of 18 and 45.
4. Be an experienced contact lens wearer.
5. Be an eyecare clinician or clinician-in-training.
6. Flat and steep keratometry readings within 40 to 50D.
7. Clear, healthy corneas with no irregular astigmatism.
8. Normal, healthy conjunctiva in both eyes.
9. Be able to provide corneal topography measurements.
10. Be able to provide manifest refraction measurements.

Exclusion Criteria:

1. Irregular corneal astigmatism.
2. Use of topical or systemic antihistamines within the previous week.
3. Use of topical ophthalmic drops within the previous two days.
4. History of corneal surgery.
5. Currently pregnant or lactating.
6. Systemic disease that would interfere with contact lens wear.
7. Previous diagnosis of dry eye syndrome.

Primary outcomes:
measure: Corneal Oxygen Uptake Rate
timeFrame: up to 45 seconds
Secondary outcomes:
Other outcomes:
Locations:
city: Columbus
country: United States
facility: Rev1 Ventures
state: Ohio
Study officials:
References:
Clinical trial NCT05648318: Comparison of Oral Lactulose Versus Polyethylene Glycol for Bowel Preparation in Low-risk Patients
Official title: 1L Oral Lactulose is an Effective Regimen for Bowel Preparation in Low-risk Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Colonic Neoplasms
Keywords: colonoscopy
bowel preparation
Lead sponsor: First People's Hospital of Hangzhou
Sponsor class: OTHER
First posted: 2022-12-13
Enrollment: 255
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SCREENING

Brief summary: Adequate quality of bowel preparation(BP) is essential for colonoscopy. In recently, Kang suggested that for low-risk patients, single dose of 2L PEG is an effective regimen for bowel preparation.However, due to the poor palatability, there still more than 30% patients with 2L regimen experienced nausea or vomiting in our center.

Oral lactulose is a treatment for constipation. Several studies have compared the effectiveness between use PEG and lactulose for colonoscopy preparation in average-risk patients. However, the data in low-risk patients is vacant. The objective of current study was to compared the effectiveness of bowel preparation and patient tolerance using lactulose and 2L PEG regimen in low-risk patients.


Eligibility criteria: Inclusion Criteria:

* Patients over 18 years old and with low-risk were eligible. Patients were considered as low risk if they did not meet any of the following risk factors: age\>70 years old, body mass index (BMI)\>25Kg/m2, constipation, Parkinson's disease, diabetes, history of stroke or spinal cord injury, use of tricyclic antidepressant or narcotics.

Exclusion Criteria:

* (1) history of colorectal resection; (2) Known or suspected colonic stricture or obstructing tumor; (3) Known or suspected colonic perforation; (4) toxic colitis or megacolon; (5) use of prokinetic agents or purgatives within 7 days; (6) hemodynamic instability; (7) pregnancy or lactation; (8) inability to provide informed consent.

Primary outcomes:
measure: Bowel preparation
timeFrame: 1hour
Secondary outcomes:
measure: Adverse events
timeFrame: 1hour
measure: Willingness to repeat bowel preparation
timeFrame: 1hour
measure: Adenoma detection rate
timeFrame: 7 days
measure: Cecal intubation rate
timeFrame: 1hour
measure: insertion time
timeFrame: 1hour
measure: withdrawal time
timeFrame: 1hour
Other outcomes:
Locations:
city: Hangzhou
country: China
facility: Hangzhou first people's Hospital
state: Zhejiang
Study officials:
affiliation: First People's Hospital of Hangzhou
name: Xiaofeng Zhang, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01929213: Clinical Trial to Investigate the Pharmacokinetic Drug Interaction Between Udenafil and Bosentan After Oral Administration
Official title: A Randomized, Open-label, Multiple Dose, Three-treatment, Three-period, Six-sequence Williams Design to Investigate the Pharmacokinetic Drug Interaction Between Udenafil and Bosentan After Oral Administration in Healthy Volunteers
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
Conditions: Healthy Volunteers
Lead sponsor: Dong-A ST Co., Ltd.
Sponsor class: INDUSTRY
Collaborators: name: Dong-A ST Co., Ltd.
First posted: 2013-08-27
Enrollment: 30
Sex: ALL
Minimum age (years): 20
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: This study is designed to investigate the pharmacokinetic drug interaction and safety after oral administration of Udenafil(DA-8159) and Bosentan in healthy volunteers.

Design: Randomized, open-label, multiple-dose, three-treatment, three-period, six-sequence, Williams design

Investigational Product: Udenafil, Bosentan


Eligibility criteria: Inclusion Criteria:

* healthy volunteers between the ages of 20 to 45 years old within the range of BMI between 18.5 and 25(Body Mass Index)
* having neither congenital/chronic diseases nor pathological symptoms/findings as results of medical examination
* doctor determines to be suitable as subjects within 4 weeks ago before administration

Exclusion Criteria:

* Hypersensitivity(or history of hypersensitivity) to Udenafil, Bosentan and PDE5 inhibitors
* Active Liver Diseases or exceed 1.25 times the normal range of AST, ALT
* Gastrointestinal diseases or surgeries that affect absorption of drug
* Excessive drinking(exceed 210g/week) and excessive caffeine(exceed 5cups/day)
* Smoking over 10 cigarettes per day
* pregnant or nursing female volunteers

Primary outcomes:
measure: Udenafil, Bosentan C max,ss
timeFrame: Blood gathering point: 0, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12h of D1, D15, D29(if Udenafil adminstrated alone), 0 h of D7, D21, D35, 0, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36 h of D8, D22, D36
measure: Udenafil, Bosentan AUC tau,ss
timeFrame: Blood gathering point: 0, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12h of D1, D15, D29(if Udenafil adminstrated alone), 0 h of D7, D21, D35, 0, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36 h of D8, D22, D36
Secondary outcomes:
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Severance Hospital Clinical Trial Center
Study officials:
affiliation: Severance Hospital
name: Min Soo Park
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03653013: Neuropsychological Consultation as Part of Pediatric Diabetes Care: Does it Improve Glycemic Control and Family Functioning?
Official title: Neuropsychological Consultation as Part of Pediatric Diabetes Care: Does it Improve Glycemic Control and Family Functioning?
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Diabetes
Glycinemia
Lead sponsor: NYU Langone Health
Sponsor class: OTHER
First posted: 2018-08-31
Enrollment: 50
Sex: ALL
Minimum age (years): 10
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a randomized controlled open label study design (study team will not be blinded) to measure whether including targeted neuropsychological consultations as part of pediatric diabetes care informs treatment and educational planning, improves glycemic control, and improves quality of life. Patients will be randomized 1:1 ratio to Group 1-Control group and Group 2-Neuropsychological consultation group.


Eligibility criteria: Inclusion Criteria:

* diagnosed with type 1 diabetes and followed for their care at the NYU pediatric diabetes center
* English speaking families

Exclusion Criteria:

* not english speaking
* diagnosed with type 1 diabetes within the last 6 months

Primary outcomes:
measure: Improved Glycemic Control measured by assessment of glycemic control (HgbA1C)
timeFrame: 0 Months
measure: Improved Glycemic Control measured by assessment of glycemic control (HgbA1C)
timeFrame: 3 Months
measure: Improved Glycemic Control measured by assessment of glycemic control (HgbA1C)
timeFrame: 6 Months
measure: Improved Glycemic Control measured by assessment of glycemic control (HgbA1C)
timeFrame: 9 Months
Secondary outcomes:
Other outcomes:
Locations:
city: New York
country: United States
facility: NYU Langone Health
state: New York
Study officials:
affiliation: NYU Langone Health
name: Mary Gallagher, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06394713: A Study to Evaluate the Efficacy and Safety of QLF31907 Combination Therapy in Patients With Advanced Malignant Tumors
Official title: A Phase 1b/2 Trial to Evaluate the Efficacy and Safety of QLF31907 (PD-L1/4-1BB Bi-specific Antibody) Combination Therapy in Patients With Advanced Malignant Tumors
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: PHASE1
PHASE2
Conditions: Advanced Malignant Neoplasm
Lead sponsor: Qilu Pharmaceutical Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2024-05-01
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SEQUENTIAL
Primary purpose: TREATMENT

Brief summary: This study is designed to evaluate the safety and efficacy of QLF31907 combination therapy in advanced malignant tumors.


Eligibility criteria: Inclusion Criteria:

1. subjects voluntarily participated and signed a written informed consent form;
2. age ≥18 years, male or female;
3. ECOG PS 0-1;
4. histopathologically diagnosed advanced malignant tumors;
5. at least 1 measurable lesion according to RECIST v1.1 criteria or Lugano (2014) criteria;
6. adequate organ function;

Exclusion Criteria:

1. previous treatment with 4-1BB agonist or 4-1BB recombinant fusion protein;
2. received anti-tumor therapy within 4 weeks prior to the first study treatment;
3. history of autoimmune disease;
4. history of other active malignancies within 3 years prior to the first treatment;
5. history of serous cardiovascular events;

Primary outcomes:
measure: phase Ib: Dose-limiting toxicity(DLT)
timeFrame: 28 days
measure: phase2: objective response rate(ORR)
timeFrame: up to 2 years
Secondary outcomes:
measure: adverse events (AEs) of QLF31907 combination therapy
timeFrame: up to 2 years
measure: area under the concentration-time curve (AUC) of QLF31907
timeFrame: up to 2 years
measure: Immunogenicity of QLF31907
timeFrame: up to 2 years
measure: overall survival(OS)
timeFrame: up to 2 years
measure: maximum plasma concentration (Cmax) of QLF31907
timeFrame: up to 2 years
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT04304313: A Pilot Study of Sildenafil in COVID-19
Official title: A Pilot Study of Sildenafi in the Treatment of COVID-19
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE3
Conditions: COVID-19
Lead sponsor: Tongji Hospital
Sponsor class: OTHER
First posted: 2020-03-11
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Observe the efficacy and safety of G1(Sildenafil citrate tablets) in patients with COVID-19 under clinical actual diagnosis and treatment conditions


Eligibility criteria: Inclusion Criteria:

1. Patients diagnosed as COVID-19:

   1. mild patient: fever,respiratory and other symptoms, the manifestation of pneumonia can be seen on imaging.
   2. severe patients: meet the definition of severe pneumonia(comply with any of the followings): Shortness of breath,RR≥30 bpm;In a resting state:SPO2≤93%;PaO2/FiO2≤300mmHg.
2. Age≥18 years old,unlimited gender.
3. Patients who cannot stop the following drugs during the trial:erythromycin or strong inhibitors of CYP3A4 (such as saquinavir,ketoconazole,itraconazole),nonspecific inhibitors of CYP (such as cimetidine),HIV protease inhibitors (such as ritonavir).
4. Willing to participate in this study,signed Informed Consent and willing to participate in regular follow-up during the study.

Exclusion Criteria:

1. Suffer from severe cognitive impairment or mental illness.
2. Pregnant and lactating women.
3. Patients taking nitric oxide drugs and nitrates in any dosage form.
4. Patients with malignant tumors;AMI, stroke or life-threatening arrhythmias within 6 months;hereditary pigmented retinitis;heart failure or unstable angina pectoris of coronary heart disease;patients with severe hypotension and hypertension.
5. Patients who are allergic to the study drug or the researcher believes it is not appropriate.
6. Participate in other clinical studies at the same time.

Primary outcomes:
measure: Rate of disease remission
timeFrame: 14 days
measure: Rate of entering the critical stage
timeFrame: 14 days
measure: Time of entering the critical stage
timeFrame: 14 days
Secondary outcomes:
measure: Rate of no fever
timeFrame: 14 days
measure: Rate of respiratory symptom remission
timeFrame: 14 days
measure: Rate of lung imaging recovery
timeFrame: 14 days
measure: Rate of C-reactive protein (CRP) recovery
timeFrame: 14 days
measure: Rate of Biochemical criterion (CK, ALT, Mb) recovery
timeFrame: 14 days
measure: Rate of undetectable viral RNA (continuous twice)
timeFrame: 14 days
measure: Time for hospitalization
timeFrame: 14 days
measure: Rate of adverse event
timeFrame: 14 days
Other outcomes:
Locations:
city: Wuhan
country: China
facility: Department and Institute of Infectious Disease
state: Hubei
Study officials:
References:
citation: Sultana J, Crisafulli S, Gabbay F, Lynn E, Shakir S, Trifiro G. Challenges for Drug Repurposing in the COVID-19 Pandemic Era. Front Pharmacol. 2020 Nov 6;11:588654. doi: 10.3389/fphar.2020.588654. eCollection 2020.
Clinical trial NCT01313013: A Question Prompt Sheet for Depressive Outpatients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Depression
Lead sponsor: Technical University of Munich
Sponsor class: OTHER
First posted: 2011-03-11
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: question prompt sheet for outpatients suffering from depression. effects on patient-doctor-communication during the consultation.


Eligibility criteria: Inclusion Criteria:

* 18-65 years
* male and female patients
* outpatients
* informed consent

Exclusion Criteria:

* poor German language skills

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References: